Rajesh Shetty, MD
Ophthalmology · Jacksonville, FLNPI 1538159454
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 38.9% of the total. Reporting peaked in 2023 at $10,673 and has fallen 73.6% since, to $2,821 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 569 payments — averaging $86.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$19K
- Alcon$17K
- AbbVie$2K
- Sight Sciences, Inc.$2K
- Glaukos Corporation$1K
- NEW World Medical,inc.$1K
- plus $6K from 30 others
Across 81 payments — averaging $7530.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$494K
- Glaukos Corporation$87K
- AbbVie$29K
What the payments were for
- Consulting fees$6,27013%
- Speaking & faculty fees$22,59946%
- Grants$2000%
- Travel & lodging$1,5523%
- Food & beverage$18,79638%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 27 | $19,243 |
| Alcon | 209 | $16,864 |
| AbbVie(2 entities) | 65 | $2,325 |
| Sight Sciences, Inc. | 59 | $2,303 |
| Glaukos Corporation | 25 | $1,334 |
| NEW World Medical,inc. | 28 | $1,153 |
| Rxsight Inc | 13 | $1,130 |
| Biotissue Holdings Inc. | 14 | $715 |
| Harrow Eye, LLC | 25 | $426 |
| Bausch & Lomb Americas Inc. | 13 | $424 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $404 |
| Lensar, Inc. | 13 | $361 |
| Carl Zeiss Meditec USA, Inc. | 6 | $338 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $334 |
| Nova Eye, Inc. | 1 | $258 |
| Amgen | 3 | $257 |
| Sun Pharmaceutical Industries Inc. | 11 | $257 |
| Oyster Point Pharma, Inc. | 4 | $211 |
| Kala Pharmaceuticals, Inc. | 1 | $191 |
| Iridex Corporation | 2 | $152 |
| Dutch Ophthalmic, USA | 1 | $133 |
| Dompe US, Inc. | 1 | $125 |
| Carl Zeiss Meditec, Inc. | 2 | $109 |
| Rayner Intraocular Lenses Limited | 3 | $93 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Topcon Healthcare, Inc. | 2 | $43 |
| Heru, Inc. | 1 | $38 |
| Novartis | 2 | $29 |
| Ivantis, Inc | 2 | $29 |
| Medtronic | 1 | $27 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyepoint US, Inc. | 1 | $19 |
| Omeros Corporation | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Topcon Healthcare Solutions, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$22,875
- Rocklatan$22,875
- ARGOS$7,261
- Clareon$1,171
- OMNI(R) SURGICAL SYSTEM (US)$993
- RXSIGHT CONTACT LENS$768
- RXSIGHT INJECTOR CARTRIDGE$768
- RXSIGHT INJECTOR HANDPIECE$768
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$768
- LIGHT ADJUSTABLE LENS (LAL)$555
- LenSx$505
- Ahmed Glaucoma Valve$499
- Kahook Dual Blade$499
- XEN GLAUCOMA TREATMENT SYSTEM$481
- DURYSTA$346
- LUMIGAN$320
- iStent$303
- Clareon PanOptix Pro$252
- TEPEZZA$229
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$213
How this compares
$49,455 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 144 | $82,424 |
| RhopressaNetarsudil Mesylate | 33 | $24,349 |
| RestasisCyclosporine | 20 | $21,696 |
| Alphagan PBrimonidine Tartrate | 40 | $19,589 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 104 | $17,427 |
| Brinzolamide | 72 | $15,966 |
| Latanoprost | 1,266 | $15,856 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $15,046 |
| ProlensaBromfenac Sodium | 33 | $13,234 |
| XiidraLifitegrast | 13 | $13,078 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $12,806 |
| Travoprost | 65 | $12,594 |
| Prednisolone Acetate | 288 | $12,579 |
| VyzultaLatanoprostene Bunod | 24 | $12,050 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 512 | $11,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $2,325 | $138,754236 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $19,243 | $37,15553 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $424 | $25,12837 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate | $404 | $18,49958 claims |
| AlconSimbrinza, Azopt | $16,864 | $15,42233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.